Oppenheimer raised the firm’s price target on Atai Life Sciences (ATAI) to $16 from $14 and keeps an Outperform rating on the shares as recent dynamics bode well for BPL-003. As large cap players vie for leadership in neuroscience, psychiatry is increasingly in focus while acquisitions of smaller players are an important source of innovation, Oppenheimer notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- Psychedelic: Filament reports compassionate use approval for psilocybin
- ATAI Life Sciences: Strategic Positioning and Diversified Portfolio Drive Buy Rating
- Atai Life Sciences price target raised to $15 from $10 at H.C. Wainwright
- Sarepta upgraded, Tapestry downgraded: Wall Street’s top analyst calls
- Atai Life Sciences initiated with an Outperform at Oppenheimer